Targeting Myc in triple negative breast cancer models through the dual inhibition of PIM kinases and CDK9

被引：0
|
作者：
Haws, Hillary [1 ]
Kim, Wontak [1 ]
Siddiqui-Jain, Adam [1 ]
Bearss, David J. [1 ]
Warner, Steven L. [1 ]
Whatcott, Clifford J. [1 ]
机构：
[1] Tolero Pharmaceut Inc, Lehi, UT USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-B178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B178
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
    McLaughlin, Ronan P.
    He, Jichao
    van der Noord, Vera E.
    Redel, Jevin
    Foekens, John A.
    Martens, John W. M.
    Smid, Marcel
    Zhang, Yinghui
    van de Water, Bob
    BREAST CANCER RESEARCH, 2019, 21 (1)
  • [22] Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
    Demirsoy, Seyma
    Tran, Ha
    Liu, Joseph
    Li, Yunzhan
    Yang, Shengyu
    Aregawi, Dawit
    Glantz, Michael J.
    Jacob, Naduparambil K.
    Walter, Vonn
    Schell, Todd D.
    Olmez, Inan
    CANCERS, 2024, 16 (12)
  • [23] Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
    Zeng, Mei
    Kwiatkowski, Nicholas P.
    Zhang, Tinghu
    Nabet, Behnam
    Xu, Mousheng
    Liang, Yanke
    Quan, Chunshan
    Wang, Jinhua
    Hao, Mingfeng
    Palakurthi, Sangeetha
    Zhou, Shan
    Zeng, Qing
    Kirschmeier, Paul T.
    Meghani, Khyati
    Leggett, Alan L.
    Qi, Jun
    Shapiro, Geoffrey I.
    Liu, Joyce F.
    Matulonis, Ursula A.
    Lin, Charles Y.
    Konstantinopoulos, Panagiotis A.
    Gray, Nathanael S.
    ELIFE, 2018, 7
  • [24] Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models
    Forostyan, Tetyana V.
    Weagel, Evita
    Matsumura, Yuta
    Tyagi, Ethika
    Foulks, Jason M.
    Whatcott, Clifford J.
    Siddiqui-Jain, Adam
    Bearss, David J.
    Warner, Steven L.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [25] CDK4/6 inhibition in early stage triple negative breast cancer
    Kietzman, William B.
    Ory, Virginie
    Saenz, Fransisco
    Sharif, Ghada
    Wellstein, Anton
    Riegel, Anna T.
    CANCER RESEARCH, 2017, 77
  • [26] PIM1 kinase inhibition halts the growth of MYC-overexpressing triple-negative breast tumors
    Horiuchi, Dai
    Zhou, Alicia Y.
    Corella, Alexandra N.
    Yau, Christina
    Lawson, Devon A.
    Bazarov, Alexey V.
    Yaswen, Paul
    McManus, Michael T.
    Werb, Zena
    Welm, Alana L.
    Goga, Andrei
    CANCER RESEARCH, 2014, 74 (19)
  • [27] CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
    Cheung, Anthony
    Chenoweth, Alicia M.
    Quist, Jelmar
    Sow, Heng Sheng
    Malaktou, Christina
    Ferro, Riccardo
    Hoffmann, Ricarda M.
    Osborn, Gabriel
    Sachouli, Eirini
    French, Elise
    Marlow, Rebecca
    Lacy, Katie E.
    Papa, Sophie
    Grigoriadis, Anita
    Karagiannis, Sophia N.
    CANCERS, 2022, 14 (14)
  • [28] Fatty acid inhibition reduces MYC expression in triple-negative breast cancer
    Sritharan, N.
    Lee, J.
    Goga, A.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S108 - S108
  • [29] Aurora kinases inhibition enhances neoadjuvant chemotherapy response in triple negative breast cancer
    Xu, Jia
    Liu, Chang
    Ning, Bohan
    Kucukdagli, Ali Cem
    Chen, Yunjia
    CANCER RESEARCH, 2024, 84 (07)
  • [30] Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
    Xia, Lin
    Zheng, Zaozao
    Liu, Jun-Yi
    Chen, Yu-Jie
    Ding, Jiancheng
    Hu, Guo-Sheng
    Hu, Ya-Hong
    Liu, Suling
    Luo, Wen-Xin
    Xia, Ning-Shao
    Liu, Wen
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (06) : 707 - 722
12345